Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.48 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2064797 | 0.88 | CHRNB2 (0.40) | CYP2C9CYP2C19DPP4DPP8DPP9 | |
| SCHEMBL2064933 | 0.85 | DPP4 (0.45) | CYP2C9CYP2C19DPP4DPP8DPP9 | |
| SCHEMBL2064934 | 0.85 | DPP4 (0.45) | CYP2C9CYP2C19DPP4DPP8DPP9 | |
| SCHEMBL20188020 | 0.81 | CYP2C19 (0.60) | CYP2C9CYP2C19DPP4DPP8DPP9 | |
| SCHEMBL3538355 | 0.81 | CYP2C9 (0.51) | CYP2C9CYP2C19DPP4DPP8DPP9 | |
| SCHEMBL3538352 | 0.81 | CYP2C9 (0.51) | CYP2C9CYP2C19DPP4DPP8DPP9 | |
| SCHEMBL20193319 | 0.77 | CYP2C19 (0.56) | CYP2C9CYP2C19DPP4DPP8DPP9 | |
| SCHEMBL7683287 | 0.76 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL118352 | 0.75 | CHRNB2 (0.57) | CYP2C9CYP2C19DPP4DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL3338273 | 0.75 | DPP4 (0.59) | CYP2C9CYP2C19DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190704-A1 | AZAADAMANTANE ESTER AND CARBAMATE DERIVATIVES AND METHODS OF USE THEREOF | SCHRIMPF MICHAEL R (US) | 2012-07-26 | — | — | US | disclosed |
| EP-2129672-B1 | AZAADAMANTANE ESTER AND CARBAMATE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LAB (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-2129672-A1 | AZAADAMANTANE ESTER AND CARBAMATE DERIVATIVES AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2009-12-09 | — | — | EP | disclosed |
| US-20080255178-A1 | Azaadamantane Ester and Carbamate Derivatives and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2008-10-16 | — | — | US | disclosed |
| WO-2008118742-A1 | AZAADAMANTANE ESTER AND CARBAMATE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255178-A1 | Azaadamantane Ester and Carbamate Derivatives and Methods of Use Thereof | CYP51A1, ALKBH5, AZI2 | CYP2C9 294/4885CYP2C19 453/4885DPP4 141/4885 |
| US-20120190704-A1 | AZAADAMANTANE ESTER AND CARBAMATE DERIVATIVES AND METHODS OF USE THEREOF | CYP51A1, ALKBH5, AZI2 | CYP2C9 294/4885CYP2C19 453/4885DPP4 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.